SRSF2 mutation cooperates with ASXL1 truncated alteration to accelerate leukemogenesis-Reference-Cited by-同舟云学术

SRSF2 mutation cooperates with ASXL1 truncated alteration to accelerate leukemogenesis

Published:2023-11-28 Issue: Volume: Page:
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Sui Pinpin^ORCID,Ge Guo^ORCID,Chen Shi,Bai Jiaojiao,Rubalcava Ivan P.^ORCID,Yang Hui,Guo Ying,Zhang Peng^ORCID,Li Ying,Medina Edward A.,Xu Mingjiang^ORCID,Abdel-Wahab Omar,Bradley Robert^ORCID,Yang Feng-Chun^ORCID

Funder

Foundation for the National Institutes of Health

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-023-02094-6.pdf

Reference12 articles.

1. Gelsi-Boyer V, Trouplin V, Roquain J, Adelaide J, Carbuccia N, Esterni B, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2010;151:365–75.

2. Patel JP, Gonen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079–89.

3. Thol F, Friesen I, Damm F, Yun H, Weissinger EM, Krauter J, et al. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol. 2011;29:2499–506.

4. Brecqueville M, Rey J, Bertucci F, Coppin E, Finetti P, Carbuccia N, et al. Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes Cancer. 2012;51:743–55.

5. Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, et al. The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2015;47:1326–33.